Company News-Bio-Thera Solutions, Ltd.

Bio-Thera Solutions’ Golimumab Biosimilars Receive FDA Approval as First Biosimilars to Simponi® and Simponi Aria®; Accord BioPharma to Commercialize IMMGOLIS™ (golimumab-sldi) and IMMGOLIS INTRI™ (golimumab-sldi) in the United States

2026-05-18

GUANGZHOU, China --- Bio-Thera Solutions (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline...

查看详情

11-102025

Bio-Thera Solutions Expands Partnership with Dr. Reddy’s through an Exclusive Commercialization and License Agreement for BAT2306, a Proposed Biosimilar Candidate to Cosentyx® (Secukinumab), in Southeast Asia

Guangzhou, China; November 10, 2025: Bio-TheraSolutions (688177:SH; “Bio-Thera”), a commercial-stage biopharmaceuticalco...
11-102025

Bio-Thera Solutions Announces the Launch of STARJEMZA® (ustekinumab-hmny) in the United States

GUANGZHOU,China - Bio-Thera Solutions (688177.SH), a commercial-stage biopharmaceutical companydeveloping innovative the...
10-092025

Bio-Thera Solutions Announces Expansion of Partnership with Intas Pharmaceuticals for BAT2506, a Proposed Biosimilar Referencing Simponi® (golimumab), through Exclusive Commercialization and License A

GUANGZHOU, China --- Bio-Thera Solutions (688177:SH), a commercial-stage biopharmaceuticalcompany developing a pipeline ...

上一页 1 2 3 4 5 ··· 下一页